On April 15, 2020 ArcherDX, Inc., reported that new data from its research collaboration with UCL and the Francis Crick Institute as part of the Cancer Research UK-funded UCL-sponsored TRACERx study was chosen to be presented by UCL on Tuesday, April 28 at 2:15 p.m. ET during the 2020 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Virtual Annual Meeting (Press release, ArcherDX, APR 15, 2020, View Source [SID1234556362]). The TRACERx study, a translational research program taking place over nine years, follows patients with lung cancer from diagnosis to either disease relapse or cure after surgery, tracking and analyzing how their cancer develops.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Clinicians are eager to expand precision oncology into early-stage cancer, when the cancer is typically easier to cure compared to late-stage cancer. Current monitoring methods, such as diagnostic imaging and cancer antigen tests, lack resolution and accuracy needed to monitor early-stage disease. Our technology allows for clinicians to use the assays in local labs and maintain control of the data," said Jason Myers, Ph.D., Chief Executive Officer and co-founder, ArcherDX. "This collaboration with UCL and the Francis Crick Institute aims to detect minimal residual disease, earlier by tracking personalized, patient-specific mutations."
As part of an ongoing collaboration, TRACERx1 investigators, led by Professor Charles Swanton, Group Leader, UCL and the Francis Crick Institute, and Dr. Christopher Abbosh, Principal Clinical Fellow, UCL, are utilizing ArcherDX’s technology to detect low-volume minimal residual disease at high levels of sensitivity to achieve TRACERx’s goal of a more personalized approach to developing cancer treatments.
Oral Presentation Details
The virtual meeting is free and available to anyone by registering at aacr.org.
Presentation Title:
Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study
Presenter:
Christopher Abbosh, M.D., Principal Clinical Fellow, University College London
Session Title:
Early Detection and ctDNA
Session Date and Time:
Tuesday, April 28 at 2:15 p.m. ET
Abstract Number:
2025